Scarica l'app Stockscreener
20.72
3.03%
0.61
Dopo l'orario di chiusura:
20.72
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio's (ANAB) "Neutral" Rating Reiterated at UBS Group - MarketBeat
UBS Adjusts Price Target on AnaptysBio to $20 From $18, Maintains Neutral Rating - MarketScreener
What is Wedbush's Estimate for AnaptysBio Q4 Earnings? - MarketBeat
Federated Hermes Inc. Sells 36,910 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 9.8%Should You Sell? - MarketBeat
Wedbush Raises AnaptysBio (NASDAQ:ANAB) Price Target to $45.00 - MarketBeat
AnaptysBio Receives Hold Rating from Truist Financial with $20 Target - AInvest
Federated Hermes Inc. Has $154,000 Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Leerink Partnrs Forecasts Stronger Earnings for AnaptysBio - MarketBeat
Wedbush Weighs in on AnaptysBio's Q3 Earnings (NASDAQ:ANAB) - MarketBeat
What moving averages say about AnaptysBio Inc.Downside Control Plan With Support Analysis - Newser
AnaptysBio Reports Q2 2025 Financial Results and Updates - TipRanks
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $45.00 - Defense World
Can machine learning forecast AnaptysBio Inc. recoveryInvestment Timeline and ROI Summary Report - Newser
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
AnaptysBio Inc. stock trend forecastSecure Entry Point Finder with Analysis - Newser
Why AnaptysBio Inc. stock attracts strong analyst attentionProven Trading System with Consistent Gains - Newser
AnaptysBio Inc (ANAB) Stock: Uncovering 52-Week Market Trends - investchronicle.com
AnaptysBio's Promising Pipeline and Financial Stability Support Buy Rating - AInvest
AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating - TipRanks
BIT Capital GmbH Purchases Shares of 25,422 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
DCF Advisers LLC Invests $648,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth - AInvest
Wedbush Raises Price Target on AnaptysBio to $45 From $40, Keeps Outperform Rating - MarketScreener
AnaptysBio (ANAB) Target Price Raised by Wedbush | ANAB Stock Ne - GuruFocus
AnaptysBio: Wedbush raises PT to $45 from $40, maintains Outperform rating. - AInvest
AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 18c - StreetInsider
How to recover losses in AnaptysBio Inc. stockFree Expert Verified Stock Trade Ideas - Newser
AnaptysBio (ANAB) Q2 Revenue Jumps 103% - The Globe and Mail
AnaptysBio earnings beat by $0.18, revenue topped estimates - Investing.com Canada
AnaptysBio reports Q2 EPS ($1.34), consensus ($1.58) - TipRanks
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
AnaptysBio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
AnaptysBio Reports Positive Phase 2b Data for Rosnilimab in Rheumatoid Arthritis and Completes Enrollment for Ulcerative Colitis Trial - Quiver Quantitative
Anaptys Delivers Strong RA Trial Results and Eyes $75M Milestone as Pipeline Advances - Stock Titan
Palmoplantar Pustulosis Clinical Trials, Companies, - openPR.com
Palmoplantar Pustulosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., AnaptysBio, Inc., Boeh - Barchart.com
AnaptysBio Inc. Crosses 200 Day MA — Signal or NoiseProfit Focused Stock Screener Results Released - metal.it
Skandinaviska Enskilda Banken AB publ Purchases New Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Palmoplantar Pustulosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., Anaptysbio, Inc., Boeh - Menafn
How many analysts rate AnaptysBio Inc. as a “Buy”Invest confidently with professional advice - Jammu Links News
Is AnaptysBio Inc. stock overvalued or undervaluedSuperior investment outcomes - Jammu Links News
AnaptysBio (NASDAQ:ANAB) Stock Price Down 9.8%Time to Sell? - MarketBeat
What is AnaptysBio Inc. company’s growth strategyMaximize portfolio growth with expert advice - Jammu Links News
What institutional investors are buying AnaptysBio Inc. stockPhenomenal wealth increase - Jammu Links News
How does AnaptysBio Inc. generate profit in a changing economyHigh-impact stock picks - Jammu Links News
What are AnaptysBio Inc. company’s key revenue driversFree Buy/Sell Signal Notifications - Jammu Links News
AnaptysBio Inc. Stock Analysis and ForecastRapidly growing investment returns - Jammu Links News
When is AnaptysBio Inc. stock expected to show significant growthAchieve consistent double-digit growth rates - Jammu Links News
How does AnaptysBio Inc. compare to its industry peersBuild a winning portfolio with smart picks - Jammu Links News
What makes AnaptysBio Inc. stock price move sharplyUnlock exclusive stock market insights - Jammu Links News
Is it the right time to buy AnaptysBio Inc. stockTriple returns potential - Jammu Links News
What catalysts could drive AnaptysBio Inc. stock higher in 2025Identify undervalued stocks ready to soar - Jammu Links News
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):